CBTRUS统计报告:2018-2022年美国原发性脑及其他中枢神经系统肿瘤
CBTRUS基于美国CDC国家癌症登记项目与NCI的SEER数据,统计2018-2022年美国原发脑及中枢神经系统肿瘤。全人群年均年龄调整发病率为26.05/10万,胶质母细胞瘤占恶性52.2%,脑膜瘤占非恶性57.4%,恶性5年相对生存率34.8%。
要点
- 全人群年均年龄调整发病率为26.05/10万,女性高于男性。
- 胶质母细胞瘤占所有恶性脑肿瘤的52.2%,男性更常见。
- 脑膜瘤占所有非恶性脑肿瘤的57.4%,女性更常见。
核心结论
- 2018-2022年美国原发脑及中枢神经系统肿瘤年均年龄调整发病率为26.05/10万。
- 恶性脑及中枢神经系统肿瘤的5年相对生存率为34.8%,非恶性为91.7%。
研究设计与样本
- CBTRUS汇集CDC国家癌症登记项目与NCI的SEER数据,覆盖全美人口。
- 报告统计2018-2022年原发性脑及其他中枢神经系统肿瘤的发病与死亡数据。
主要发现
- 全人群年均年龄调整发病率为26.05/10万,其中恶性6.86/10万,非恶性19.19/10万。
- 女性发病率29.67/10万高于男性22.23/10万。
- 非西班牙裔黑人发病率27.40/10万高于非西班牙裔白人26.36/10万。
- 胶质瘤占所有肿瘤的22.2%。
- 胶质母细胞瘤占所有肿瘤的13.7%、恶性肿瘤的52.2%;脑膜瘤占所有肿瘤的42.6%、非恶性肿瘤的57.4%。
关键数值与推荐
- 儿童及青少年(0-19岁)原发脑及中枢神经系统肿瘤发病率为5.99/10万。
- 2018-2022年恶性脑及中枢神经系统肿瘤死亡共88,186例,年均17,637例,年均死亡率4.41/10万。
临床怎么用
- 可为神经外科医生提供美国脑肿瘤流行病学最新基线数据。
- 有助于按年龄、性别、种族及组织学类型评估疾病负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Central Brain Tumor Registry of the United States (CBTRUS), an aggregation of data from the Centers for Disease Control and Prevention's National Program of Cancer Registries and the National Cancer Institute's Surveillance, Epidemiology and End Results program, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US). As of this report, the CBTRUS database represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors and supersedes all previous reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. Between 2018 and 2022, the average annual age-adjusted incidence rate (AAAIR) of all primary malignant and non-malignant brain and other CNS tumors was 26.05 per 100,000 population (malignant AAAIR=6.86 and non-malignant AAAIR=19.19). Incidence was higher in women compared to men (29.67 versus 22.23 per 100,000) and in non-Hispanic Black individuals compared to non-Hispanic White (27.40 versus 26.36 per 100,000), non-Hispanic American Indian/Alaska Native (24.38 per 100,000), non-Hispanic Asian or Pacific Islander (20.42 per 100,000), and Hispanic individuals of all races (24.69 per 100,000). Gliomas accounted for 22.2% of all tumors. The most commonly occurring malignant brain and other CNS histopathology was glioblastoma (13.7% of all tumors and 52.2% of all malignant tumors), and the most common non-malignant histopathology was meningioma (42.6% of all tumors [includes malignant meningioma] and 57.4% of all non-malignant tumors). Glioblastoma was more common in men, and meningioma was more common in women. In children and adolescents (ages 0-19 years), the incidence rate of all primary brain and other CNS tumors was 5.99 per 100,000 population. Overall, there were 88,186 total deaths attributed to malignant brain and other CNS tumors between 2018 and 2022, representing an average of 17,637 deaths per year and an average annual mortality rate of 4.41 per 100,000 population. The five-year relative survival rate following diagnosis of a malignant brain or other CNS tumor was 34.8%, while it was 91.7% for a non-malignant brain or other CNS tumor.
引用
- Price M, Ballard CAP, Benedetti JR, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018-2022. Neuro Oncol. 2025. PMID: 41092086. doi:10.1093/neuonc/noaf194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。